Marc Frahm

Stock Analyst

(n/a)
# 4,648
Out of 4,648 analysts
15
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:

Stocks Rated by Marc Frahm

Theravance Biopharma
Aug 6, 2024
Maintains: Hold
Price Target: $10$9
Current: $8.21
Upside: +9.62%
Incyte
May 1, 2024
Maintains: Buy
Price Target: $88$80
Current: $75.75
Upside: +5.61%
Sana Biotechnology
Aug 14, 2023
Initiates: Market Perform
Price Target: n/a
Current: $3.76
Upside: -
Cullinan Therapeutics
Jun 15, 2023
Initiates: Outperform
Price Target: n/a
Current: $15.92
Upside: -
Xilio Therapeutics
Nov 16, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.44
Upside: -
Nuvalent
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $89.53
Upside: -
Elevation Oncology
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.52
Upside: -
Janux Therapeutics
Jul 6, 2021
Initiates: Outperform
Price Target: n/a
Current: $55.87
Upside: -
Day One Biopharmaceuticals
Jun 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $14.81
Upside: -
Inozyme Pharma
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $4.42
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $2.99
Upside: -